Approved treatments for AD in Europe consist of cholinesterase inhibitors (ChEI) such as donepezil, rivastigmine and galantamine [12] for mild-to-moderate AD and the NMDA receptor antagonist memantine [13, 14] for moderate-to-severe AD. The gene discussed is BCHE; the disease is Alzheimer disease.